Marksans Pharma arm Relonchem bags UK MHRA marketing nod for oral solution to treat epilepsy
Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary Relonchem Limited has received Marketing Authorization for the product Levetiracetam Relonchem 100 mg/mL Oral Solution from the Medicines and Healthcare Products Regulatory Agency in the United Kingdom (UK MHRA).
Levetiracetam, a medication used for the treatment of epilepsy, helps in managing specific seizure types.
The product will be manufactured at the Group’s UK manufacturing facility.
Read also: Marksans Pharma bags USFDA nod for Esomeprazole Magnesium Delayed Release Capsules
Marksans Pharma Limited headquartered at Mumbai, India is engaged in Research, manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd